290 related articles for article (PubMed ID: 19713000)
1. The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase.
Darreh-Shori T; Modiri N; Blennow K; Baza S; Kamil C; Ahmed H; Andreasen N; Nordberg A
Neurobiol Aging; 2011 Jul; 32(7):1236-48. PubMed ID: 19713000
[TBL] [Abstract][Full Text] [Related]
2. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo.
Darreh-Shori T; Forsberg A; Modiri N; Andreasen N; Blennow K; Kamil C; Ahmed H; Almkvist O; Långström B; Nordberg A
Neurobiol Aging; 2011 Dec; 32(12):2320.e15-32. PubMed ID: 20538374
[TBL] [Abstract][Full Text] [Related]
3. Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism.
Darreh-Shori T; Brimijoin S; Kadir A; Almkvist O; Nordberg A
Neurobiol Dis; 2006 Nov; 24(2):326-33. PubMed ID: 16973370
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A
J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848
[TBL] [Abstract][Full Text] [Related]
5. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
7. Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease.
Varges D; Jung K; Gawinecka J; Heinemann U; Schmitz M; von Ahsen N; Krasnianski A; Armstrong VW; Zerr I
J Alzheimers Dis; 2011; 23(4):717-26. PubMed ID: 21157024
[TBL] [Abstract][Full Text] [Related]
8. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
9. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
[TBL] [Abstract][Full Text] [Related]
11. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
[TBL] [Abstract][Full Text] [Related]
12. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
13. The CDC2 I-G-T haplotype associated with the APOE epsilon4 allele increases the risk of sporadic Alzheimer's disease in Sicily.
Bosco P; Caraci F; Copani A; Spada RS; Sortino MA; Salluzzo R; Salemi M; Nicoletti F; Ferri R
Neurosci Lett; 2007 Jun; 419(3):195-8. PubMed ID: 17498878
[TBL] [Abstract][Full Text] [Related]
14. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
[TBL] [Abstract][Full Text] [Related]
15. Genetic interaction between tau and the apolipoprotein E receptor LRP1 Increases Alzheimer's disease risk.
Vázquez-Higuera JL; Mateo I; Sánchez-Juan P; Rodríguez-Rodríguez E; Pozueta A; Infante J; Berciano J; Combarros O
Dement Geriatr Cogn Disord; 2009; 28(2):116-20. PubMed ID: 19684401
[TBL] [Abstract][Full Text] [Related]
16. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels.
Laws SM; Perneczky R; Wagenpfeil S; Müller U; Förstl H; Martins RN; Kurz A; Riemenschneider M
Hum Mutat; 2005 Jul; 26(1):29-35. PubMed ID: 15895461
[TBL] [Abstract][Full Text] [Related]
17. Cerebral beta-amyloid deposition is augmented by the -491AA promoter polymorphism in non-demented elderly individuals bearing the apolipoprotein E epsilon4 allele.
Pahnke J; Walker LC; Schroeder E; Vogelgesang S; Stausske D; Walther R; Warzok RW
Acta Neuropathol; 2003 Jan; 105(1):25-9. PubMed ID: 12471457
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E epsilon4 allele frequency in elderly depressed patients with and without cerebrovascular disease.
Traykov L; Bayle AC; Latour F; Lenoir H; Seux ML; Hanon O; Péquignot R; Bert P; Moulin F; Cantegreil I; Wenisch E; Batouche F; Mehrabian S; Rotrou Jd; Rigaud AS
J Neurol Sci; 2007 Jun; 257(1-2):280-3. PubMed ID: 17337010
[TBL] [Abstract][Full Text] [Related]
19. Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.
Gabriel AJ; Almeida MR; Ribeiro MH; Carneiro D; Valério D; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
J Alzheimers Dis; 2018; 61(3):1097-1105. PubMed ID: 29254094
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease.
Tilley L; Morgan K; Grainger J; Marsters P; Morgan L; Lowe J; Xuereb J; Wischik C; Harrington C; Kalsheker N
Eur J Hum Genet; 1999 Sep; 7(6):659-63. PubMed ID: 10482954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
